<DOC>
	<DOCNO>NCT00141024</DOCNO>
	<brief_summary>The purpose study determine safety immune response investigational HIV vaccine , EP HIV-1090 , HIV uninfected adult .</brief_summary>
	<brief_title>Safety Immune Response Experimental Preventive HIV Vaccine , EP HIV-1090 , Healthy , HIV-1 Uninfected Adults</brief_title>
	<detailed_description>The worldwide HIV/AIDS epidemic may control development safe effective vaccine prevent HIV infection . DNA vaccine inexpensive construct , readily produce large quantity , stable long periods time . EP HIV-1090 DNA HIV CTL vaccine ; proteins gene code design interact CD8 cell ( CTL ) cause CD8 cell proliferation . The DNA plasmid EP HIV-1090 code protein conserve among HIV subtypes A , B , C , D , F , G , encompass HLA subtypes 85 % worldwide general population . Participants enrol study 1 year . Group 4 participant receive EP HIV-1090 placebo study entry Months 1 , 3 , 6 . There 11 study visit occur screen ; study entry ; Months 0.5 , 1 , 1.5 , 3 , 3.5 , 6 , 6.5 , 9 , 12 . A physical exam risk reduction/pregnancy prevention counsel occur visit . Participants ask adverse experience vaccination visit . Blood urine collection occur select visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Note : Groups 1 , 2 , 3 , 5 permanently discontinue enrollment per 12/26/06 letter amendment . Good general health Have access participate HIV Vaccine Trials Unit ( HVTU ) willing follow duration study Willing receive HIV test result Have understanding study Willing use acceptable form contraception Negative pregnancy test HIV vaccine prior HIV vaccine trial Immunosuppressive medication within 168 day prior first vaccination Blood product within 120 day prior first vaccination Immunoglobulin within 60 day prior first vaccination Live attenuate vaccine within 30 day prior first vaccination Investigational research agent within 30 day prior first vaccination Medically indicate subunit kill vaccine within 14 day prior first study vaccine administration , allergy treatment antigen injection within 30 day prior first vaccination Current tuberculosis prophylaxis therapy Clinically significant medical condition , abnormal physical exam finding , abnormal laboratory result , past medical history may affect current health Any medical , psychiatric , social condition would interfere study . More information criterion find protocol . Any jobrelated responsibility would interfere study Serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Active syphilis infection unless participant complete full treatment syphilis 6 month prior enrollment Unstable asthma Diabetes mellitus type 1 2 Thyroid disease thyroidectomy require treatment Serious angioedema within 3 year prior enrollment Uncontrolled hypertension Body mass index ( BMI ) 40 great BMI 35 great participant old 45 year , systolic blood pressure great 140 mm Hg , diastolic blood pressure great 90 mm Hg , smoke , know hyperlipidemia Bleeding disorder Malignancy unless surgically remove , opinion investigator , likely recur study period Seizure disorder require medication within 3 year prior enrollment Absence spleen Mental illness would interfere study Other condition , judgment investigator , would interfere study Pregnancy , breastfeeding , plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>